Epigenetic signatures in gastric cancer: current knowledge and future perspectives

• Published in: Expert review of molecular diagnostics Vol. 22; no. 12; p. 1063
• Main Authors: Sogutlu, Fatma, Pekerbas, Mert, Biray Avci, Cigir
• Format: Journal Article
• Language: English
• Published: England 02-12-2022
• Subjects: Biomarkers; DNA Methylation; Epigenesis, Genetic; Epigenomics; Humans; Stomach Neoplasms - diagnosis; Epigenetics; noncoding RNA; histone modifications; gastric cancer; methylation
• ISSN: 1744-8352
• DOI: 10.1080/14737159.2022.2159381

Gastric cancer (GC) is the fifth most common malignancy in the world and accounts for 7.7% of all cancer-related deaths. Early diagnosis of GC is critical in terms of prognosis, and aberrations at the molecular level, especially epigenetic alterations, manifest much earlier than histological findings. In recent years, there has been a great deal of research on the epigenomic profile of GC, and epigenetic alterations seem to play a more important role than genetic factors. With the introduction of epigenetic drugs into clinical use in the last decade, the importance of the epigenetic background of GC has increased considerably.
In this review, we summarize the role of methylation changes, histone modifications, and non-coding RNAs in the pathogenesis of GC and how these signatures can be used as diagnostic and therapeutic targets in clinical management.
Epigenetic alterations take place before most genetic aberrations observed in GC and may have an initiating role in the pathogenesis of GC. They can be used as biomarkers in risk calculation, early diagnosis, and evaluation of prognosis of GC, as well as treatment targets.